| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0269216310375999 |
| P953 | full work available at URL | http://journals.sagepub.com/doi/pdf/10.1177/0269216310375999 |
| P698 | PubMed publication ID | 20671005 |
| P2093 | author name string | Misha Eliasziw | |
| Penny Ma Brasher | |||
| Neil A. Hagen | |||
| Sharon M. Watanabe | |||
| Dwight E. Moulin | |||
| Patricia D. Biondo | |||
| Carla R. Stiles | |||
| P2860 | cites work | Methodologic issues in collecting data from debilitated patients with cancer near the end of life | Q30760133 |
| Symptom recording in a randomised clinical trial: paper diaries vs. electronic or telephone data capture | Q30978127 | ||
| Despite technical problems personal digital assistants outperform pen and paper when collecting patient diary data | Q31084755 | ||
| Breakthrough pain: definition, prevalence and characteristics | Q33435886 | ||
| A proposed taxonomy of terms to guide the clinical trial recruitment process | Q33582999 | ||
| Why are trials in palliative care so difficult? | Q33863148 | ||
| Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study | Q33873528 | ||
| Sublingual absorption of selected opioid analgesics | Q34040004 | ||
| Methadone use in cancer patients with pain: a review | Q34525701 | ||
| Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care | Q34539972 | ||
| Assessing clients in their natural environments with electronic diaries: rationale, benefits, limitations, and barriers. | Q36763976 | ||
| Evaluation of a palliative care service: problems and pitfalls | Q36888649 | ||
| The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews | Q37051857 | ||
| Assessment and management of breakthrough pain in cancer patients: current approaches and emerging research | Q37215376 | ||
| Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain | Q39297474 | ||
| Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief | Q39324051 | ||
| Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study | Q39335946 | ||
| A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer | Q39344435 | ||
| Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study | Q39372953 | ||
| Characterization of breakthrough pain by hospice patients and their caregivers | Q39444429 | ||
| Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations | Q39457377 | ||
| Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain | Q39517610 | ||
| A comparison of methodologies from two longitudinal community-based randomized controlled trials of similar interventions in palliative care: what worked and what did not? | Q40365590 | ||
| Methodologic issues in effectiveness research on palliative cancer care: a systematic review | Q40898443 | ||
| An update on the clinical use of methadone for cancer pain. | Q40898900 | ||
| Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study | Q43284157 | ||
| Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension tr | Q43288823 | ||
| Methadone titration in opioid-resistant cancer pain | Q44352173 | ||
| Patient compliance with paper and electronic diaries | Q47980863 | ||
| Recruiting patients into a primary care based study of palliative care: why is it so difficult? | Q50143279 | ||
| Breakthrough pain: characteristics and impact in patients with cancer pain. | Q51089873 | ||
| The acceptability of different routes of administration of analgesia for breakthrough pain | Q73287349 | ||
| Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice | Q74317837 | ||
| Recruiting into palliative care trials: lessons learnt from a feasibility study | Q77989687 | ||
| Electronic pain diary: a randomized crossover study | Q80506690 | ||
| Determination of free and protein-bound methadone and its major metabolite EDDP: enantiomeric separation and quantitation by LC/MS/MS | Q81505183 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cancer pain | Q3712728 |
| P304 | page(s) | 696-706 | |
| P577 | publication date | 2010-07-29 | |
| P1433 | published in | Palliative Medicine | Q7127852 |
| P1476 | title | A formal feasibility study of sublingual methadone for breakthrough cancer pain | |
| P478 | volume | 24 |
| Q36807866 | Canadian recommendations for the management of breakthrough cancer pain |
| Q24188053 | Opioids for the management of breakthrough pain in cancer patients |
| Q24202962 | Opioids for the management of breakthrough pain in cancer patients |
| Q33919787 | Reporting characteristics of cancer pain: a systematic review and quantitative analysis of research publications in palliative care journals. |
Search more.